Intraperitoneal administration of nesfatin‑1 stimulates glucagon‑like peptide‑1 secretion in fasted mice

Tagawa,Noriko; Ogura,Honoka; Miyawaki,Hikaru; Asakawa,Akihiro; Kato,Ikuo

doi:10.3892/mmr.2022.12894

Intraperitoneal administration of nesfatin‑1 stimulates glucagon‑like peptide‑1 secretion in fasted mice

Authors:
- Noriko Tagawa
- Honoka Ogura
- Hikaru Miyawaki
- Akihiro Asakawa
- Ikuo Kato
View Affiliations

Affiliations: Laboratory of Medical Biochemistry, Kobe Pharmaceutical University, Kobe, Hyogo 685‑8558, Japan, Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890‑8544, Japan
Published online on: November 9, 2022 https://doi.org/10.3892/mmr.2022.12894
Article Number: 7
Copyright: © Tagawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing endogenous secretion of glucagon‑like peptide (GLP)‑1 is considered a promising therapeutic approach for type 2 diabetes because decreased GLP‑1 plasma concentrations have been observed in patients with this condition. Nesfatin‑1, which is a central and peripheral anorexigenic peptide, has been reported to release GLP‑1 from enteroendocrine STC‑1 cells, although whether nesfatin‑1 stimulates GLP‑1 secretion in vivo remains to be elucidated. Previous studies have indicated that nesfatin‑1 has glucose‑lowering and insulinotropic effects in mice and rats; however, the in vivo mechanism remains unclear. The present study aimed to investigate whether peripheral administration of nesfatin‑1 increased blood concentrations of GLP‑1 and insulin in food‑deprived mice. Nesfatin‑1 was administered intraperitoneally to 18‑h fasted mice. Plasma GLP‑1 and insulin concentrations in the mice administered 2.5 µmol/kg nesfatin‑1 were higher than those in saline‑treated mice. Blood glucose concentrations in mice treated with 1.25 and 2.5 µmol/kg nesfatin‑1 were lower than those in saline‑treated mice. The mRNA expression of preproglucagon in mouse ilea after treatment with 1.25 µmol/kg nesfatin‑1 was higher than that in saline‑treated mice. The administration of 1.25 µmol/kg nesfatin‑1 raised GLP‑1 concentrations at 30 and 60 min and insulin concentrations at 30 and 60 min after injection. Furthermore, the higher level of nesfatin‑1‑induced insulin was diminished by pre‑administration of anti‑GLP‑1 antiserum. Intraperitoneally administered nesfatin‑1 increased insulin concentrations by accelerating GLP‑1 secretion. The results are the first in vivo demonstration of promotion of GLP‑1 secretion by nesfatin‑1 in the mouse, suggesting the developmental potential of nesfatin‑1 for GLP‑1 release.

View Figures

View References

1	Holst JJ, Gribble F, Horowitz M and Rayner CK: Roles of the gut in glucose homeostasis. Diabetes Care. 39:884–892. 2016. View Article : Google Scholar : PubMed/NCBI
2	Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H and Martin C: Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 21:62752020. View Article : Google Scholar : PubMed/NCBI
3	Prentki M, Matschinsky FM and Madiraju SR: Metabolic signaling in fuel-induced insulin secretion. Cell Metab. 18:162–185. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nauck MA and Meier JJ: Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 20 (Suppl 1):S5–S21. 2018. View Article : Google Scholar : PubMed/NCBI
5	Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, et al: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 443:709–712. 2006. View Article : Google Scholar : PubMed/NCBI
6	Konczol K, Pinter O, Ferenczi S, Varga J, Kovacs K, Palkovits M, Zelena D and Toth ZE: Nesfatin-1 exerts long-term effect on food intake and body temperature. Int J Obes (Lond). 36:1514–1521. 2012. View Article : Google Scholar : PubMed/NCBI
7	Gonzalez R, Tiwari A and Unniappan S: Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun. 381:643–648. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK and Randeva HS: Identification of nesfatin-1 in human and murine adipose tissue: A novel depot-specific adipokine with increased levels in obesity. Endocrinology. 151:3169–3180. 2010. View Article : Google Scholar : PubMed/NCBI
9	Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Tache Y, Sachs G and Lambrecht NW: Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology. 150:232–238. 2009. View Article : Google Scholar : PubMed/NCBI
10	Osaki A, Shimizu H, Ishizuka N, Suzuki Y, Mori M and Inoue S: Enhanced expression of nesfatin/nucleobindin-2 in white adipose tissue of ventromedial hypothalamus-lesioned rats. Neurosci Lett. 521:46–51. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang AQ, Li XL, Jiang CY, Lin L, Shi RH, Chen JD and Oomura Y: Expression of nesfatin-1/NUCB2 in rodent digestive system. World J Gastroenterol. 16:1735–1741. 2010. View Article : Google Scholar : PubMed/NCBI
12	Yang M, Zhang Z, Wang C, Li K, Li S, Boden G, Li L and Yang G: Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance. Diabetes. 61:1959–1968. 2012. View Article : Google Scholar : PubMed/NCBI
13	Marraudino M, Bonaldo B, Farinetti A, Panzica G, Ponti G and Gotti S: Metabolism disrupting chemicals and alteration of neuroendocrine circuits controlling food intake and energy metabolism. Front Endocrinol (Lausanne). 9:7662018. View Article : Google Scholar : PubMed/NCBI
14	Drougard A, Fournel A, Valet P and Knauf C: Impact of hypothalamic reactive oxygen species in the regulation of energy metabolism and food intake. Front Neurosci. 9:562015. View Article : Google Scholar : PubMed/NCBI
15	Stanley SA, Kelly L, Latcha KN, Schmidt SF, Yu X, Nectow AR, Sauer J, Dyke JP, Dordick JS and Friedman JM: Bidirectional electromagnetic control of the hypothalamus regulates feeding and metabolism. Nature. 531:647–650. 2016. View Article : Google Scholar : PubMed/NCBI
16	Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova I, Pan W, et al: Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 30:987–996. e62019. View Article : Google Scholar : PubMed/NCBI
17	Su Y, Zhang J, Tang Y, Bi F and Liu JN: The novel function of nesfatin-1: Anti-hyperglycemia. Biochem Biophys Res Commun. 391:1039–1042. 2010. View Article : Google Scholar : PubMed/NCBI
18	Gonzalez R, Perry RL, Gao X, Gaidhu MP, Tsushima RG, Ceddia RB and Unniappan S: Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. Endocrinology. 152:3628–3637. 2011. View Article : Google Scholar : PubMed/NCBI
19	Li Z, Gao L, Tang H, Yin Y, Xiang X, Li Y, Zhao J, Mulholland M and Zhang W: Peripheral effects of nesfatin-1 on glucose homeostasis. PLoS One. 8:e715132013. View Article : Google Scholar : PubMed/NCBI
20	Riva M, Nitert MD, Voss U, Sathanoori R, Lindqvist A, Ling C and Wierup N: Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res. 346:393–405. 2011. View Article : Google Scholar : PubMed/NCBI
21	Li QC, Wang HY, Chen X, Guan HZ and Jiang ZY: Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 159:72–77. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhang Z, Li L, Yang M, Liu H, Boden G and Yang G: Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 120:91–95. 2012. View Article : Google Scholar : PubMed/NCBI
23	Guo Y, Liao Y, Fang G, Dong J and Li Z: Increased nucleobindin-2 (NUCB2) transcriptional activity links the regulation of insulin sensitivity in type 2 diabetes mellitus. J Endocrinol Invest. 36:883–888. 2013.PubMed/NCBI
24	Nakata M, Manaka K, Yamamoto S, Mori M and Yada T: Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca²⁺ influx through L-type channels in mouse islet beta-cells. Endocr J. 58:305–313. 2011. View Article : Google Scholar : PubMed/NCBI
25	Maejima Y, Horita S, Kobayashi D, Aoki M, O'Hashi R, Imai R, Sakamoto K, Mori M, Takasu K, Ogawa K, et al: Nesfatin-1 inhibits voltage gated K⁺ channels in pancreatic beta cells. Peptides. 95:10–15. 2017. View Article : Google Scholar : PubMed/NCBI
26	Ramesh N, Mortazavi S and Unniappan S: Nesfatin-1 stimulates glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide secretion from STC-1 cells in vitro. Biochem Biophys Res Commun. 462:124–130. 2015. View Article : Google Scholar : PubMed/NCBI
27	Mizutani M, Atsuchi K, Asakawa A, Matsuda N, Fujimura M, Inui A, Kato I and Fujimiya M: Localization of acyl ghrelin- and des-acyl ghrelin-immunoreactive cells in the rat stomach and their responses to intragastric pH. Am J Physiol Gastrointest Liver Physiol. 297:G974–G980. 2009. View Article : Google Scholar : PubMed/NCBI
28	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
29	Shimizu H, Oh IS, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, et al: Peripheral administration of nesfatin-1 reduces food intake in mice: The leptin-independent mechanism. Endocrinology. 150:662–671. 2009. View Article : Google Scholar : PubMed/NCBI
30	Tekin T, Cicek B and Konyaligil N: Regulatory peptide nesfatin-1 and its relationship with metabolic syndrome. Eurasian J Med. 51:280–284. 2019. View Article : Google Scholar : PubMed/NCBI
31	Dumonteil E, Magnan C, Ritz-Laser B, Meda P, Dussoix P, Gilbert M, Ktorza A and Philippe J: Insulin, but not glucose lowering corrects the hyperglucagonemia and increased proglucagon messenger ribonucleic acid levels observed in insulinopenic diabetes. Endocrinology. 139:4540–4546. 1998. View Article : Google Scholar : PubMed/NCBI
32	da Silva Xavier G, Farhan H, Kim H, Caxaria S, Johnson P, Hughes S, Bugliani M, Marselli L, Marchetti P, Birzele F, et al: Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion. Diabetologia. 54:819–827. 2011. View Article : Google Scholar : PubMed/NCBI
33	Oben J, Morgan L, Fletcher J and Marks V: Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7–36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol. 130:267–272. 1991. View Article : Google Scholar : PubMed/NCBI
34	Orskov C, Wettergren A and Holst JJ: Biological effects and metabolic rates of glucagonlike peptide-1 7–36 amide and glucagonlike peptide-1 7–37 in healthy subjects are indistinguishable. Diabetes. 42:658–661. 1993. View Article : Google Scholar : PubMed/NCBI
35	Drucker DJ and Nauck MA: The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368:1696–1705. 2006. View Article : Google Scholar : PubMed/NCBI
36	Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K and Terauchi Y: Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol. 49:225–230. 2012. View Article : Google Scholar : PubMed/NCBI
37	Brunton SA and Wysham CH: GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med. 132:3–14. 2020. View Article : Google Scholar : PubMed/NCBI
38	Ahren B: DPP-4 Inhibition and the path to clinical proof. Front Endocrinol (Lausanne). 10:3762019. View Article : Google Scholar : PubMed/NCBI
39	Tolhurst G, Reimann F and Gribble FM: Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol. 587:27–32. 2009. View Article : Google Scholar : PubMed/NCBI
40	Lan H, Lin HV, Wang CF, Wright MJ, Xu S, Kang L, Juhl K, Hedrick JA and Kowalski TJ: Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol. 165:2799–2807. 2012. View Article : Google Scholar : PubMed/NCBI
41	Iwasaki Y, Sendo M, Dezaki K, Hira T, Sato T, Nakata M, Goswami C, Aok R, Arai T, Kumari P, et al: GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nat Commun. 9:1132018. View Article : Google Scholar : PubMed/NCBI
42	Feijoo-Bandin S, Rodriguez-Penas D, Garcia-Rua V, Mosquera-Leal A, Otero MF, Pereira E, Rubio J, Martinez I, Seoane LM, Gualillo O, et al: Nesfatin-1 in human and murine cardiomyocytes: Synthesis, secretion and mobilization of GLUT-4. Endocrinology. 154:4757–4767. 2013. View Article : Google Scholar : PubMed/NCBI
43	Wu D, Yang M, Chen Y, Jia Y, Ma ZA, Boden G, Li L and Yang G: Hypothalamic nesfatin-1/NUCB2 knockdown augments hepatic gluconeogenesis that is correlated with inhibition of mTOR-STAT3 signaling pathway in rats. Diabetes. 63:1234–1247. 2014. View Article : Google Scholar : PubMed/NCBI
44	Tasatargil A, Kuscu N, Dalaklioglu S, Adiguzel D, Celik-Ozenci C and Ozdem S, Barutcigil A and Ozdem S: Cardioprotective effect of nesfatin-1 against isoproterenol-induced myocardial infarction in rats: Role of the Akt/GSK-3beta pathway. Peptides. 95:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
45	Fan XT, Tian Z, Li SZ, Zhai T, Liu JL, Wang R, Zhang CS, Wang LX, Yuan JH, Zhou Y and Dong J: Ghrelin receptor is required for the effect of nesfatin-1 on glucose metabolism. Front Endocrinol (Lausanne). 9:6332018. View Article : Google Scholar : PubMed/NCBI
46	Li T, Wei S, Fan C, Tang D and Luo D: Nesfatin-1 promotes proliferation, migration and invasion of HTR-8/SVneo trophoblast cells and inhibits oxidative stress via activation of PI3K/AKT/mTOR and AKT/GSK3beta pathway. Reprod Sci. 28:550–561. 2021. View Article : Google Scholar : PubMed/NCBI
47	Su RY, Geng XY, Yang Y and Yin HS: Nesfatin-1 inhibits myocardial ischaemia/reperfusion injury through activating Akt/ERK pathway-dependent attenuation of endoplasmic reticulum stress. J Cell Mol Med. 25:5050–5059. 2021. View Article : Google Scholar : PubMed/NCBI
48	Prinz P, Goebel-Stengel M, Teuffel P, Rose M, Klapp BF and Stengel A: Peripheral and central localization of the nesfatin-1 receptor using autoradiography in rats. Biochem Biophys Res Commun. 470:521–527. 2016. View Article : Google Scholar : PubMed/NCBI
49	Rupp SK, Wolk E and Stengel A: Nesfatin-1 receptor: Distribution, signaling and increasing evidence for a G protein-coupled receptor-A systematic review. Front Endocrinol. 12:7401742021. View Article : Google Scholar : PubMed/NCBI
50	Dong J, Xu H, Wang PF, Cai GJ, Song HF, Wang CC, Dong ZT, Ju YJ and Jiang ZY: Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLoS One. 8:e833972013. View Article : Google Scholar : PubMed/NCBI
51	Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Ronne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, et al: Semaglutide lowers body weight in rodents via distributed neural pathways. JCI insight. 5:e1334292020. View Article : Google Scholar : PubMed/NCBI